The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives.
about
alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic populationEarly metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significanceLow-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibilityThe role of longitudinal cohort studies in epigenetic epidemiology: challenges and opportunitiesDoes insulin resistance drive the association between hyperglycemia and cardiovascular risk?High body mass index is an important risk factor for the development of type 2 diabetes.Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units.Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control studyRETRACTED: Leisure-time physical activity and the risk of metabolic syndrome: meta-analysis.Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT ConsortiumOne-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study.Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitusMetabolic normality in overweight and obese subjects. Which parameters? Which risks?Quantifying the improvement of surrogate indices of hepatic insulin resistance using complex measurement techniquesHbA1c, fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysis.Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity.Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts.Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and womenBody weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study.Influence of hyperinsulinemia and insulin resistance on in vivo β-cell function: their role in human β-cell dysfunction.Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver diseaseA novel test for IGT utilizing metabolite markers of glucose tolerance.Obesity and carotid artery remodeling.Metabolic syndrome: what is it and what are the implications?Migration and DNA methylation: a comparison of methylation patterns in type 2 diabetes susceptibility genes between indians and europeansPhysical activity and insulin sensitivity: the RISC study.A novel fasting blood test for insulin resistance and prediabetes.Low-grade chronic inflammation in the relationship between insulin sensitivity and cardiovascular disease (RISC) population: associations with insulin resistance and cardiometabolic risk profileCommon genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response.Influence of apolipoproteins on the association between lipids and insulin sensitivity: a cross-sectional analysis of the RISC Study.Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids.Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Measurement of insulin-mediated glucose uptake: direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp.From metabolic normality to cardiometabolic risk factors in subjects with obesity.Identification of novel biomarkers to monitor β-cell function and enable early detection of type 2 diabetes risk.Deterioration of insulin release rate response to glucose during oral glucose tolerance test is associated with an increased risk of incident diabetes in normal glucose tolerance subjects.Glucose uptake saturation explains glucose kinetics profiles measured by different tests.A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants.Insulin resistance and normal thyroid hormone levels: prospective study and metabolomic analysis.
P2860
Q21136353-2475858B-6142-4BB6-B0C5-F04FD8C2958AQ28279396-E7EE721D-538E-49CC-AA5F-AC1F86D58411Q28651068-4F1D64AD-AB72-4BEC-ACE7-D070E6277F4BQ28727710-DF78B649-DFC8-40C7-872F-073BE46968D1Q28728387-2DB5D28D-0C40-4495-9696-C7DA538B732EQ30422924-581A13D2-85E7-4205-A7A7-2B19C665FF93Q33305022-3A79AB36-B031-4DE2-916B-AA778D393B96Q33373532-9DB2E762-6624-4D68-8B61-F71EA442E8C1Q33574498-91305EE1-2FF7-4459-9DA2-B887C1BE75A9Q33600199-5B33EA11-A983-4BBF-BE1E-46E9110EC456Q33678580-E1D0178E-1691-407C-974F-E55A58426282Q33808313-FEDC1B9B-7C0F-4716-9164-FC199CD60C0BQ34157549-27EB2D6F-CE8C-4297-9E49-CCF262C4DE34Q34325851-67BB7BB6-64F4-4A17-9C20-BAF74BD9C2D4Q34559044-B15C779D-B254-4004-8C14-37E62063D3C0Q34559688-F18EF9DE-AA3D-4312-8D8C-B904C147A022Q34940230-FE846F0D-8FAC-44B6-9AD7-2A2B4D3B9AB0Q35043457-2D4C61E1-2E09-48B5-82C1-F4E7C8B5ACD0Q35063254-61E47A4E-83FB-4718-A135-3E681357B628Q35561076-34EE654C-9FD7-46E2-9494-28C01D6E4CDCQ35809618-663D1749-07FA-444A-AA32-FD6128E4F998Q35830440-5E142F75-2CA2-4E2A-9EB1-086D40B5E808Q36022447-6755842E-A1FB-491B-8DF5-8CEB9D4FDA17Q36209835-11558CAC-8E2C-4FA8-B6A4-ADEC6F61C9B5Q36807943-E5DB42FD-FB35-4059-8B37-36B82BEFA9B2Q36906316-0B6EDA3D-4160-47B2-833C-3D938A8C8D42Q36954280-43FFDF40-15AC-45EA-9050-0984699F6B9CQ37235932-78AE063E-C9E3-4365-8AAA-A442DBF65004Q37259911-9FFE55C2-4275-4B4D-8D0E-DEA6B480DD89Q37331224-2205B404-9AF1-448A-90BD-55DBAD023CC8Q37333477-EB224A6A-97A0-4816-A1F3-82A9E6F50C3DQ37380298-2CD8CC90-657F-440F-B4E3-2A0949843F2BQ37568754-EEF30776-CBF5-4294-B186-157819B7F197Q37586176-929148B0-5692-462F-964F-C9571A591860Q38326870-DA3022AA-9D34-4433-8685-BFE5A14608B3Q38636706-9CBF9081-135D-4DFC-A0CB-7A039D574625Q38648813-5B24684F-4454-403B-A441-37FCDA22F2BFQ39721911-84F287DD-2975-4D5D-A6F2-C186AFF93B8AQ40206988-E1C02F20-1811-4928-BB98-474FBA056FC2Q40314221-FDF0F387-6CD0-4FD3-9F1E-2002DD1350D2
P2860
The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The EGIR-RISC STUDY (The Europ ...... I. Methodology and objectives.
@en
type
label
The EGIR-RISC STUDY (The Europ ...... I. Methodology and objectives.
@en
prefLabel
The EGIR-RISC STUDY (The Europ ...... I. Methodology and objectives.
@en
P2093
P2860
P1433
P1476
The EGIR-RISC STUDY (The Europ ...... I. Methodology and objectives.
@en
P2093
E Ferrannini
Report prepared on behalf of the EGIR-RISC Study Group
S W Coppack
P2860
P2888
P304
P356
10.1007/S00125-004-1335-5
P577
2004-02-14T00:00:00Z
P5875
P6179
1021379691